MOLECULAR SUBTYPING, PROGNOSIS AND TREATMENT OF PROSTATE CANCER

摘要

Disclosed herein are new prognostic molecular markers for prostate cancer. More specifically, the invention has identified that overexpression or amplification of at least one of AURKA or MYCN define a distinct subgroup of prostate cancer that is predisposed to the development of lethal NEPC, who will benefit from early intervention.